GlassScriptPhysician profile
Joseph Vozzolo
NPI 1023314895
$12,200.61
in general payments reported to CMS, 2019-2025
37 companies · $2,401 in 2025
The $2,401 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,165 · 2020: $893 · 2021: $1,668 · 2022: $2,065 · 2023: $2,358 · 2024: $1,651 · 2025: $2,401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,401 · Education: $8.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,401.47 |
| Education | $8.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,891.17 | 2019-2025 | Watchman Flx, Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,408.83 | 2020-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $1,066.98 | 2019-2025 | |
| Amgen INC. | $935.49 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $678.30 | 2019-2024 | Aveir, Jot Dx |
| Aop Health US, LLC | $612.29 | 2025 | Rapiblyk |
| Merck Sharp & Dohme LLC | $602.33 | 2021-2025 | Verquvo |
| Novo Nordisk INC | $552.01 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $490.66 | 2019-2025 | |
| Celgene Corporation | $476.63 | 2023-2025 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $453.64 | 2019-2025 | Farxiga, Brilinta |
| Janssen Pharmaceuticals, INC | $426.54 | 2021-2024 | Xarelto |
| Medtronic, INC. | $376.89 | 2021-2025 | Selectsecure, Micra |
| E.R. Squibb & Sons, L.L.C. | $341.61 | 2019-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $279.67 | 2023-2025 | Nexletol |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Vozzolo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.